NRAS and melanoma: We showed that TTCC blockers reduce the migration rates and invasive potential of BRAFV600E-mutant melanoma cells due to autophagy inhibition, with no significant effect in NRAS-mutant melanoma cells (Table 1; Figure 2) [20,66].